Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease?
Rabelink
T J
TJ
Department of Nephrology and Hypertension, University Medical Center Utrecht, Netherlands. t.rabelink@digd.azu.nl
Stroes
E S
ES
Bouter
K P
KP
Morrison
P
P
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D002318:Cardiovascular Diseases / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism; D003928:Diabetic Nephropathies / Q000378:metabolism; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000378:metabolism / Q000502:physiology*; D000072396:Endothelin-Converting Enzymes; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000209:etiology* / Q000517:prevention & control*; D008666:Metalloendopeptidases; D012084:Renin-Angiotensin System / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D004791:Enzyme Inhibitors; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes